Literature DB >> 30606787

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Mrinal M Patnaik1, Prateek A Pophali2, Terra L Lasho2, Christy M Finke2, Pedro Horna3, Rhett P Ketterling4, Naseema Gangat2, Abhishek A Mangaonkar2, Animesh Pardanani2, Ayalew Tefferi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30606787      PMCID： PMC6545828          DOI： 10.3324/haematol.2018.208082

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

2.  DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik; Daniela Barraco; Terra L Lasho; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-12-07       Impact factor: 10.047

3.  Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

Authors:  Ayalew Tefferi; Maura Nicolosi; Mythri Mudireddy; Natasha Szuber; Christy M Finke; Terra L Lasho; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Naseema Gangat; Carmela Mannarelli; Tiziana Fanelli; Paola Guglielmelli; Alessandro M Vannucchi
Journal:  Am J Hematol       Date:  2017-12-18       Impact factor: 10.047

4.  Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis.

Authors:  Ayalew Tefferi; Sahrish Shah; Mythri Mudireddy; Terra L Lasho; Daniela Barraco; Curtis A Hanson; Rhett P Ketterling; Michelle A Elliott; Mrinal S Patnaik; Animesh Pardanani; Naseema Gangat
Journal:  Br J Haematol       Date:  2017-12-19       Impact factor: 6.998

Review 5.  Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2018-06       Impact factor: 10.047

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.

Authors:  Jennifer Chapman; Julia T Geyer; Mahsa Khanlari; Adrienne Moul; Carmen Casas; Scot T Connor; Yao-Shan Fan; Justin M Watts; Ronan T Swords; Francisco Vega; Attilio Orazi
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842

8.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Authors:  M M Patnaik; R Itzykson; T L Lasho; O Kosmider; C M Finke; C A Hanson; R A Knudson; R P Ketterling; A Tefferi; E Solary
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

9.  Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.

Authors:  Mrinal M Patnaik; Rangit Vallapureddy; Fevzi F Yalniz; Curtis A Hanson; Rhett P Ketterling; Terra L Lasho; Christy Finke; Aref Al-Kali; Naseema Gangat; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-11-03       Impact factor: 10.047

10.  Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis.

Authors:  M M Patnaik; M M Timm; R Vallapureddy; T L Lasho; R P Ketterling; N Gangat; M Shi; A Tefferi; E Solary; K K Reichard; D Jevremovic
Journal:  Blood Cancer J       Date:  2017-07-21       Impact factor: 11.037
View more
  7 in total

Review 1.  Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.

Authors:  Andrew T Kuykendall; Eric Padron
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 2.  Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.

Authors:  Giacomo Coltro; Mrinal M Patnaik
Journal:  Curr Oncol Rep       Date:  2019-11-14       Impact factor: 5.075

Review 3.  Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Authors:  Mrinal M Patnaik; Terra L Lasho
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum.

Authors:  Xavier Calvo; David Roman-Bravo; Nieves Garcia-Gisbert; Juan Jose Rodriguez-Sevilla; Sara Garcia-Avila; Lourdes Florensa; Joan Gibert; Concepción Fernández-Rodríguez; Marta Salido; Anna Puiggros; Blanca Espinet; Luis Colomo; Beatriz Bellosillo; Ana Ferrer; Leonor Arenillas
Journal:  Blood Adv       Date:  2022-07-12

5.  RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.

Authors:  Ryan M Carr; Denis Vorobyev; Terra Lasho; David L Marks; Ezequiel J Tolosa; Alexis Vedder; Luciana L Almada; Andrey Yurcheko; Ismael Padioleau; Bonnie Alver; Giacomo Coltro; Moritz Binder; Stephanie L Safgren; Isaac Horn; Xiaona You; Eric Solary; Maria E Balasis; Kurt Berger; James Hiebert; Thomas Witzig; Ajinkya Buradkar; Temeida Graf; Peter Valent; Abhishek A Mangaonkar; Keith D Robertson; Matthew T Howard; Scott H Kaufmann; Christopher Pin; Martin E Fernandez-Zapico; Klaus Geissler; Nathalie Droin; Eric Padron; Jing Zhang; Sergey Nikolaev; Mrinal M Patnaik
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

6.  How I diagnose and treat chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

Review 7.  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Authors:  Peter Valent; Attilio Orazi; Michael R Savona; Mrinal M Patnaik; Francesco Onida; Arjan A van de Loosdrecht; Detlef Haase; Torsten Haferlach; Chiara Elena; Lisa Pleyer; Wolfgang Kern; Tea Pemovska; Gregory I Vladimer; Julie Schanz; Alexandra Keller; Michael Lübbert; Thomas Lion; Karl Sotlar; Andreas Reiter; Theo De Witte; Michael Pfeilstöcker; Klaus Geissler; Eric Padron; Michael Deininger; Alberto Orfao; Hans-Peter Horny; Peter L Greenberg; Daniel A Arber; Luca Malcovati; John M Bennett
Journal:  Haematologica       Date:  2019-05-02       Impact factor: 9.941
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.